Paramore to head up Emdeon corporate strategy
NASHVILLE, Tenn. Emdeon has named Miriam Paramore senior vice president of corporate strategy. Under this new title, Paramore will be responsible for strategic planning for the future growth of the company and to explain to business partners just exactly how many businesses Emdeon is entangled in.
Most recently, Paramore was a partner with Commonwealth Leverage, a business development and investment company focused on health information technology, eHealth and health care services. She has also held several executive management positions including chief executive officer of both a health care information clearinghouse and a health care technology consulting company.
“Miriam is a respected expert with a proven executive track record across payer, provider and vendor organizations,” said George Lazenby, chief executive officer, Emdeon Business Services. “Over the years, I have been impressed with Miriam’s deep understanding of our business, her national thought leadership and her passion for transforming healthcare through the effective use of information. She is a great addition to our senior management team and will help to focus our resources where we can have the most strategic impact on the healthcare industry.”
Santen completes Phase III testing of eye drug
NEW YORK Inspire Pharmaceuticals announced Friday a $1.25 million milestone payment from Japan-based company Santen Pharmaceutical for the completion of Phase III testing of the eye drug diquafosol tetrasodium, also known as DE-089. The two companies have a collaborative agreement to develop the drug.
DE-089 is designed to treat such eye-surface diseases as dry eye. Santen expects to file for marketing approval in Japan by June, and also plans to market the drug throughout Asia. Pending approval of DE-089 by regulatory agencies, Santen will market the drug while Inspire will receive royalties on net sales.
New York-based Inspire discovers, develops and commercializes ocular and respiratory drugs. Santen specializes in ocular and anti-rheumatic drugs and had headquarters in Osaka, Japan.
Salix receives FDA approvable letter for Balsalazide colitis treatment
RALEIGH, N.C. Salix Pharmaceuticals has received an approvable letter from the Food and Drug Administration for its ulcerative colitis drug Balsalazide Tablet NDA, the company announced May 16. The drug is designed to treat mild-to-moderate active ulcerative colitis in patients 18 years and older. The disease causes ulcers in the lining of the rectum and colon.
Salix has headquarters in Raleigh, N.C., and specializes in drugs to treat gastrointestinal disorders. The company markets such drugs as Colazal (balsalazide disodium) capsules 750 mg, Xifaxan (rifaximin) tablets 200 mg, Osmoprep (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP) tablets and Moviprep (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution.